Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

811
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
811

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies.

The Journal of infectious diseases·2026
Same author

Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice.

NPJ vaccines·2026
Same author

Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.

Journal of virology·2026
Same author

Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques.

Immunity·2026
Same author

Cross-coronavirus host susceptibility loci influence disease severity through immune mediators.

bioRxiv : the preprint server for biology·2026
Same author

Binding of 14-3-3 stabilises recombinant AMPKγ2-containing complexes.

The Biochemical journal·2026
Same journal

A human-specific genetic modifier reconfigures large-scale cortical network dynamics underlying behavioral performance.

bioRxiv : the preprint server for biology·2026
Same journal

<i>Staphylococcus aureus</i> uses a eukaryotic-like uridyltransferase to make UDP-GlcNAc for cell wall synthesis.

bioRxiv : the preprint server for biology·2026
Same journal

Dynamic redistribution of eIF4F controls cap-dependent translation initiation.

bioRxiv : the preprint server for biology·2026
Same journal

When does additional information improve accuracy of RNA secondary structure prediction?

bioRxiv : the preprint server for biology·2026
Same journal

Normative brain-state trajectories reveal deviation from healthy aging in Alzheimer's disease.

bioRxiv : the preprint server for biology·2026
Same journal

Noradrenergic infraslow rhythm during sleep is the critical link between heart-rate dynamics and memory consolidation.

bioRxiv : the preprint server for biology·2026
See all related articles

Related Experiment Video

Updated: Dec 17, 2025

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.3K

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.

Kizzmekia S Corbett1, Darin Edwards2, Sarah R Leist3

  • 1Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Bethesda, Maryland, 20892; United States of America.

Biorxiv : the Preprint Server for Biology
|June 25, 2020
PubMed
Summary
This summary is machine-generated.

A novel mRNA vaccine (mRNA-1273) targeting the prefusion-stabilized SARS-CoV-2 spike protein effectively generated neutralizing antibodies and T cell responses in mice, demonstrating protection against infection without adverse effects.

More Related Videos

Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro
09:26

Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro

Published on: June 6, 2025

938
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.6K

Related Experiment Videos

Last Updated: Dec 17, 2025

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.3K
Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro
09:26

Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro

Published on: June 6, 2025

938
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.6K

Area of Science:

  • Vaccinology
  • Immunology
  • Virology

Background:

  • The COVID-19 pandemic necessitates the development of effective SARS-CoV-2 vaccines.
  • Pre-clinical research on betacoronavirus spike proteins utilized atomic-level structures to guide immunogen design, enhancing expression and immunogenicity through stabilizing mutations.

Approach:

  • Leveraging established immunogen design principles, rapid manufacturing of an mRNA vaccine (mRNA-1273) was initiated upon release of SARS-CoV-2 sequences.
  • The vaccine expresses a prefusion-stabilized SARS-CoV-2 spike trimer.

Key Points:

  • mRNA-1273 vaccination in mice induced robust neutralizing antibody titers.
  • Significant CD8 T cell responses were observed post-vaccination.
  • The vaccine conferred protection against SARS-CoV-2 infection in both the lungs and nasal passages of mice.
  • No evidence of immunopathology was detected in vaccinated mice.

Conclusions:

  • The prefusion-stabilized spike protein mRNA vaccine (mRNA-1273) demonstrates promising immunogenicity and protective efficacy in a pre-clinical model.
  • These findings support the ongoing clinical development of mRNA-1273, including Phase 2 trials and progression towards Phase 3 efficacy evaluation.